Creative Peptides is a development stage biopharmaceutical company, engaged in the discovery and development of biopharmaceutical drugs to treat long-term complications of Type 1 diabetes. Creative Peptides’ lead drug development project is currently in phase II clinical trials.
The company was founded in 1996 by leading scientists in the field of research at the Karolinska Institute and the Royal Institute of Technology in Stockholm and is based in Stockholm, Sweden.